Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

except per share) Three Months Ended Twelve Months Ended December 31, December 31, 2008 2007 2008 2007 Revenues: Collaborative and other research and development $34,240 $28,172 $56,561 $71,238 Expenses: Research and development 22,060 29,114 73,327 94,052 General and administrative 2,376 2,486 10,399 9,466 Total expenses 24,436 31,600 83,726 103,518 Income (loss) from operations 9,804 (3,428) (27,165) (32,280) Interest and other income 266 1,145 2,433 3,225 Net income (loss) $10,070 $(2,283) $(24,732) $(29,055) Basic and diluted net income (loss) per common share $0.26 $(0.06) $(0.65) $(0.89) Basic weighted average shares outstanding 38,126 37,954 38,062 32,771 Diluted weighted average shares outstanding 38,355 37,954 38,062 32,771 Balance Sheet Data (in thousands) December 31, 2008 December 31, 2007 (Unaudited) (Note 1) Cash, cash equivalents and securities $63,314 $85,008 Receivables from collaborations 11,982 39,128 Total assets 84,692 142,717 Accumulated deficit (249,268) (224,536) Stockholders' equity 46,426 64,905 Note 1: Derived from audited financial statements.


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced the addition ... to their offering. , Global Market Report ... Trypsin globally and regionally ( Europe , ... Latin America etc.). It captures Trypsin ... report focuses on three primary areas; manufacture methods & technology ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
(Date:2/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... that develops and commercializes proprietary technologies and products for ... results for the fiscal first quarter ended December  31, ... Canadian dollars (CAD), unless otherwise stated. ... business from our existing customers and add to our ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Trial in Medullary Thyroid Cancer Planned to Initiate ... 16 ,Exelixis, Inc. (Nasdaq: EXEL ) announced ... Drug Administration (FDA) have reached agreement on the ... anticancer compound targeting,MET, RET, and VEGFR2, via the ...
... Thermage Inc. To, Drive Coapt,s Growth In ... June 13 Coapt Systems, Inc.,developer of bioabsorbable implants ... and sports medicine markets, announced today the,appointment of Laureen ... as a member of the company,s Board of Directors. ...
... landmark IRIS trial, which established Gleevec as standard ... of care, - Study did not ... molecular responses with 800 vs. 400 ... optimize treatment benefit for individual ...
Cached Biology Technology:Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 2Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 2Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 4Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 6Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 7Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 8Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 9Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 10Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 11Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 12Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 13
(Date:1/22/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a ... the recent success of the Wocket™ smart wallet at CES 2015 in ... was named as one of the "11 Hot Products at CES" in ... At CES So Far" by Newseveryday.com and "The top 10 gadgets from ...
(Date:1/22/2015)... , January 22, 2015 , ... year  The European Patent Office to present a video ... British nominations to be featured: Christofer Toumazou and ... former finalists and winners of the Award   Starting ...
(Date:1/22/2015)... has launched its new NXG series of time clocks with ... higher standard for collecting attendance and labor data and complements ... touch screen interface and seamless connection to cloud-based iSolved, the ... for the small to mid-size employer. The G2 ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2
... researchers have identified the neurocircuit that controls the brain's ... be possible to understand psychiatric disorders, such as anxiety ... brain. , They accomplished this using an adapted version ... that enables analysis of function in the brain. , ...
... the January/February 2007 issue of Physiological and Biochemical Zoology, ... may respond to water diversion and climate change. Endangered ... spawn, and a lake in Western China, where they ... and becoming increasingly more saline--leading to surprising adjustments to ...
... blood oxygen levels of a baby during labor--expected to ... benefit, report researchers in a National Institutes of Health ... saturation monitoring, was designed for use along with electronic ... measure changes in fetal oxygen levels. Designers of ...
Cached Biology News:Emotional control circuit of brain's fear response discovered 2Emotional control circuit of brain's fear response discovered 3Climate change has surprising effect on endangered naked carp 2Technology for monitoring fetal oxygen during labor offers no apparent benefit 2Technology for monitoring fetal oxygen during labor offers no apparent benefit 3
Request Info...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Biology Products: